• Paul Loubet, Pierre Verger, Vered Abitbol, Laurent Peyrin-Biroulet, and Odile Launay.
• IAME, UMR 1137, INSERM, Paris Diderot University, Sorbonne Paris Cité, Paris, France; AP-HP, Bichat-Claude Bernard Hospital, Infectious Diseases Department, Paris, France.
• Dig Liver Dis. 2018 Jun 1; 50 (6): 563-567.

BackgroundDespite specific immunization guidelines for immunocompromised patients, there is a dearth of studies on inflammatory bowel disease (IBD) population in France.AimsTo estimate the prevalence and predictors of influenza and pneumococcal vaccination rates in a sample of French IBD adults.MethodsAn anonymous online survey was submitted to members of several French immunocompromised patients' associations during the winter 2016.ResultsOverall, there were 199/1625 (12%) participants with an IBD. Among these, 32% were <30 years old, 85% were male, and 62% were treated with immunosuppressive therapy. Self-reported influenza vaccine uptake was 34% (95% CI [28-41]) and 38% (95% CI [31-44]) for pneumococcal vaccines. Healthcare provider's (HCP) recommendation for vaccination (adjusted OR 12.7 95% CI [5.6-28.8]), immunosuppressive therapy (aOR 2.3 [1.1-5.3]), better knowledge of vaccination (aOR 3.2 [1.1-9.2]) and favorable attitudes towards vaccination (aOR 3.4 [1.2-9.5]) were positively associated with influenza vaccine uptake. Vaccine recommendation by HCPs was the only independently associated factor with pneumococcal vaccines uptake (OR 187.7 [24.8-1422.5]).ConclusionImmunization rates in our sample do not reach recommended levels. Factors associated with vaccination included high knowledge, favorable attitudes towards vaccination and recommendation for vaccination. This underlines the role of health care providers in contact with IBD patients.Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

32 keywords...

hide…